Targeting the Immune Checkpoint in Cancer: Is this a Viable Treatment Option for AML? by Steven J Coles in Open Access Journal of Oncology and Medicine in Lupine Publishers
The immune suppressive mechanisms displayed by malignant cells are
considered a central process in the pathogenesis of cancer. Research in
this area has gained significant momentu mover the past 20 years, with
several immune checkpoints identified, including; CTLA-4, CD200/CD200R, Tim-3/Galectin-9 and PD-L1/PD-1 (Figure 1). Whilst characterising the
molecular basis of leukaemia for risk stratification remains at the
forefront of AML research; this must now extend to understating how the
seimmune checkpoint path ways fit into the equation.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.